A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients

Trial Profile

A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2016

At a glance

  • Drugs CJM 112 (Primary) ; Secukinumab
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 10 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
    • 08 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top